Wu Vincent T, Lorenzen Allison W, Beck Anna C, Reid Vincent J, Sugg Sonia L, Howe James R, Pollard Janet H, Lal Geeta, Weigel Ronald J
Departments of Surgery and Radiology, University of Iowa, Iowa City, IA.
Departments of Surgery and Radiology, University of Iowa, Iowa City, IA.
Surgery. 2017 Jan;161(1):147-155. doi: 10.1016/j.surg.2016.06.066. Epub 2016 Nov 15.
Management of Graves disease includes antithyroid drugs, I therapy, or thyroidectomy. Our aim was to review our institutional experience with definitive treatments for Graves disease.
This was a retrospective review of patients undergoing I therapy (n = 295) or thyroidectomy (n = 103) for Graves disease (2003-2015). Demographic, clinical, pathology, and outcome data were collected from institutional databases.
I therapy patients were older (39.1 years vs 33.4 years, P = .001). There was no difference in the presence of ophthalmopathy between groups. A larger proportion of children received thyroidectomy than I therapy (17.1% vs 9.2%, P = .026). The success rate of the first I therapy dose was 81.4%. Overall success rate, including additional doses, was 90.1%. Rapid turnover of iodine correlated with I therapy failure (58.3% rapid turnover failure vs 14.9% non-rapid turnover failure, P < .05). All surgical patients underwent total or near-total thyroidectomy. I therapy complications included worsening thyrotoxicosis (1%) and deteriorating orbitopathy (0.7%). Operative complications were higher than I therapy complications (P < .05) but were transient. There was no worsening orbitopathy or recurrent Graves disease among surgical patients.
A higher proportion of pediatric Graves disease patients underwent thyroidectomy than I therapy. Rapid turnover suggested more effective initial management with operation than I therapy. Although transient operative complications were high, I therapy complications included worsening of Graves orbitopathy among those with pre-existing orbitopathy.
格雷夫斯病的治疗方法包括抗甲状腺药物、碘治疗或甲状腺切除术。我们的目的是回顾我们机构对格雷夫斯病进行确定性治疗的经验。
这是一项对2003年至2015年因格雷夫斯病接受碘治疗(n = 295)或甲状腺切除术(n = 103)的患者的回顾性研究。从机构数据库收集人口统计学、临床、病理学和结局数据。
碘治疗组患者年龄较大(39.1岁对33.4岁,P = 0.001)。两组间眼病的发生率无差异。接受甲状腺切除术的儿童比例高于碘治疗组(17.1%对9.2%,P = 0.026)。首次碘治疗剂量的成功率为81.4%。包括追加剂量在内的总体成功率为90.1%。碘的快速周转与碘治疗失败相关(快速周转失败率为58.3%,非快速周转失败率为14.9%,P < 0.05)。所有手术患者均接受了全甲状腺或近全甲状腺切除术。碘治疗的并发症包括甲状腺毒症恶化(1%)和眼眶病恶化(0.7%)。手术并发症高于碘治疗并发症(P < 0.05),但为暂时性。手术患者中未出现眼眶病恶化或格雷夫斯病复发。
接受甲状腺切除术的儿童格雷夫斯病患者比例高于碘治疗组。快速周转表明手术作为初始治疗比碘治疗更有效。虽然手术的暂时性并发症较高,但碘治疗的并发症包括已有眼眶病患者的格雷夫斯眼眶病恶化。